Marktinformationen
- Nachrichtendetail
-
24.06.2024 09:12:16 - dpa-AFX: Takeda Announces Approval Of LIVTENCITY In Japan
BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Takeda (TAK) announced that LIVTENCITY
has been approved by the Japanese Ministry of Health, Labour and Welfare for
post-transplant cytomegalovirus infection/disease that is refractory to existing
anti-CMV therapies. The company noted that the LIVTENCITY is the first and only
post-transplant anti-CMV treatment approved in Japan. The approval is primarily
based on the results of the Phase 3 SOLSTICE trial.
As of June 2024, LIVTENCITY is approved in more than 30 countries for
post-transplant CMV refractory to prior therapies, including major markets:
Japan, the United States, Canada, Australia, the European Union and China.
For More Such Health News, visit rttnews.com.
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
has been approved by the Japanese Ministry of Health, Labour and Welfare for
post-transplant cytomegalovirus infection/disease that is refractory to existing
anti-CMV therapies. The company noted that the LIVTENCITY is the first and only
post-transplant anti-CMV treatment approved in Japan. The approval is primarily
based on the results of the Phase 3 SOLSTICE trial.
As of June 2024, LIVTENCITY is approved in more than 30 countries for
post-transplant CMV refractory to prior therapies, including major markets:
Japan, the United States, Canada, Australia, the European Union and China.
For More Such Health News, visit rttnews.com.
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
TAKEDA PHARM.CO.LTD. | 853849 | Frankfurt | 24,310 | 05.07.24 21:49:39 | +0,190 | +0,79% | 0,000 | 0,000 | 24,270 | 24,310 |
